Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05806749 · ClinicalTrials.gov registry record · Phase 1
Immunological Tolerance in Patients With Mismatched Kidney Transplants
A Phase 1 study of Chronic Kidney Diseases and End-Stage Kidney Disease, sponsored by University of California, Los Angeles.
- Active
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
- 1
- Study location
NCT05806749: Active Phase 1 study of Chronic Kidney Diseases and End-Stage Kidney Disease, sponsored by University of California, Los Angeles.
NCT05806749 is a Phase 1 study of Chronic Kidney Diseases and End-Stage Kidney Disease that is active but no longer recruiting, run by University of California, Los Angeles. The registered enrollment target is 16 participants, below the 445-participant average among 73 other Chronic Kidney Diseases trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05806749, a Phase 1 study of Chronic Kidney Diseases and End-Stage Kidney Disease, is active but no longer recruiting, sponsored by University of California, Los Angeles.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
This study seeks to determine if administration of the drug belumosudil (KD025) will be safe and improve transplant tolerance in subjects undergoing combined Human Leukocyte Antigen (HLA) single haplotype-matched related or 0-3 antigen (at A, B, C, DR) HLA mismatched unrelated living donor kidney and hematopoietic stem cell transplantation.
Primary Outcome
Measure percentage of patients alive and percentage of patients with a functioning graft at 12 months
Conditions Studied
Interventions
- COMBINATION_PRODUCT Donor CD34+, CD3+. and belumosudil
Study Locations (1)
California
- University of California, Los Angeles - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2023-07-07 |
| Est. Completion | 2028-08 |
| Phase | Phase 1 |
What the registry record for NCT05806749 still lists
NCT05806749 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 445-participant average among 73 other Chronic Kidney Diseases trials with a reported enrollment target (96% lower).
The record links to 4 conditions, with Chronic Kidney Diseases appearing as the primary indexed condition, and to 1 intervention - of which Donor CD34+, CD3+. and belumosudil is the first listed.
NCT05806749 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05806749 about?
NCT05806749 is a clinical study titled "Immunological Tolerance in Patients With Mismatched Kidney Transplants". This study seeks to determine if administration of the drug belumosudil (KD025) will be safe and improve transplant tolerance in subjects undergoing combined Human Leukocyte Antigen (HLA) single haplotype-matched related or 0-3 antigen (at A, B, C, DR) HLA mismatched unrelated living donor kidney an...
What is the current status of trial NCT05806749?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2023-07-07. Estimated completion is 2028-08.
What conditions does trial NCT05806749 study?
This clinical trial studies the following conditions: Chronic Kidney Diseases, End-Stage Kidney Disease, Kidney Transplant Failure and Rejection, Immunological Tolerance.
What interventions are being tested in trial NCT05806749?
The interventions under investigation include: Donor CD34+, CD3+. and belumosudil (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT05806749?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05806749 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Kidney Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05806749's enrollment target sits among peer trials
16 71st of 73 higher than 3 of 73 other Chronic Kidney Diseases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Kidney Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease
RECRUITING · Phase 1
-
Delayed Immunological Tolerance in Patients With Well-functioning Pre-existing HLA-matched Kidney Transplants
RECRUITING · Phase 1
-
Study of DISC-0974 to Assess the Safety, Tolerability, PK and PD of DISC-0974 in Participants With CKD and Anemia
ACTIVE NOT RECRUITING · Phase 1
-
Safety and Tolerability of Vertebral Bone Marrow-derived Mesenchymal Stem Cells (BM-MSC) in Real World Scenarios of Patients With Chronic Kidney Disease (CKD)
RECRUITING
-
SAVE-FistulaS: the SelfWrap-Assisted ArterioVEnous Fistulas Study
RECRUITING · NA
-
Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI